Financials
Financial year 2025
European Drug Development Consulting from Amay, company number BE0540806771, closed financial year 2025 with a result of € 223,735 after tax. For that financial year European Drug Development Consulting recorded a gross margin of € 319,886 and equity of € 30,078. Compared with financial year 2024, the result moved from € 218,993 to € 223,735. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.
€ 30,078
▲ 47% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 223,735
▲ 2% vs 2024
Profit after tax over the fiscal year.
€ 68,799
▼ 2% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 214,118 paid out
96 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 17,456
▼ 21% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4,204
▼ 18% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 101,967 | € 277,337 | € 318,409 | € 319,886 | |
| Profit after taxes | € 53,562 | € 178,698 | € 218,993 | € 223,735 | ▲ 2% |
| Equity | € 20,460 | € 20,460 | € 20,460 | € 30,078 | ▲ 47% |
| Total debts | € 145,226 | € 161,145 | € 144,290 | € 132,955 | ▼ 8% |
| Cash | € 70,991 | € 88,972 | € 70,137 | € 68,799 | ▼ 2% |
| Land & buildings | € 6,261 | € 6,931 | € 16,307 | € 23,587 | ▲ 45% |
| Retained profit | € 1,860 | € 1,860 | € 1,860 | € 11,478 | ▲ € 9,618 |
| Dividend | € 66,940 | € 178,698 | € 218,993 | € 214,118 | ▼ 2% |
| Bank debt | € 34,745 | € 8,767 | € 0 | € 0 | |
| Balance sheet total | € 165,686 | € 181,605 | € 164,750 | € 163,032 | ▼ 1% |
Key figures of European Drug Development Consulting, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to European Drug Development Consulting?
What happened at European Drug Development Consulting in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 223,735 (▲ 2% vs 2024). Source: NBB ↗
- New establishment in Amay. KBO
- Start of the company according to the CBE. KBO
In short
From € 53,562 profit in 2022 to € 223,735 profit in 2025.
Paid € 243,739 in corporate taxes since 2022.
Best year ever: 2025, with € 223,735 profit.
Paid out € 678,747 in dividends to the owners in total.
A new publication or filing at European Drug Development Consulting? We notify you, reason included.
Follow European Drug Development ConsultingDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind European Drug Development Consulting is Jean-Louis POPLAVSKY.
Directors
According to the 2025 annual accounts
Jean-Louis POPLAVSKY
Director
Establishments
Establishment units
Physical locations of this company
Rue du Tambour(Jeh) 4
4540 Amay
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0540.806.771
- VAT number
- BE 0540.806.771
- Registered office
- Rue du Tambour(Jeh) 4, 4540 Amay
- Names & denominations
- European Drug Development Consulting · E.D.D.C.
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 October 2013
- Peppol
- Active · Active since 6 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Adviesbureaus op het gebied van public relations en communicatie
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering